Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Chronic Rhinosinusitis Without Nasal Polyps Crssnp Market

DelveInsight’s ‘Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)-Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Chronic Rhinosinusitis without Nasal Polyps, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geographies Covered     

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Disease Understanding and Treatment Algorithm

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Overview

Rhinosinusitis is a broad umbrella term covering multiple disease entities, including Acute Rhinosinusitis (ARS), Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), and Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). Chronic rhinosinusitis (CRS) is a common complex inflammatory disease, defined as persistent sinonasal symptoms lasting for at least 12 weeks.

 

Chronic rhinosinusitis (CRS) is a disease, in which both genetic and environmental factors contribute to its pathogenesis.  Chronic rhinosinusitis in adults in most guidelines is characterized by at least 8-12 weeks of at least two symptoms, like nasal blockage/obstruction/congestion, nasal discharge (anterior/posterior nasal drip), facial pain/pressure, and/or reduction or loss of smell and either endoscopic signs of disease or relevant CT scan changes.

 

Chronic rhinosinusitis (CRS) has been divided into two categories based on different phenotypes, Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) and Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) subgroups not only differ phenotypically and appear to have distinct pathogenesis and clinical presentations. Chronic rhinosinusitis without nasal polyps (CRSsNP) is more prevalent than Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Certain diseases predispose to whereas others are associated with Chronic Rhinosinusitis without Nasal Polyps (CRSsNP).

 

The mucosal lining in patients with Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) shows basement membrane thickening, goblet cell hyperplasia, limited sub-epithelial edema, prominent fibrosis, and mononuclear cell infiltration on histological evaluation. Clinically, patients with Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) generally tend to present with facial pain and purulent drainage.

 

Medical treatment consisting of nasal corticosteroids (sprays/drops) and antibiotics with anti-inflammatory activities is the first step in treatment, but surgery is indicated for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in the case of failure. There are clear diagnosis and management schemes for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) for general practitioners; nose, and throat specialists; and ear, nose, and throat specialists.

 

Investigating the pathomechanisms of chronic rhinosinusitis and the introduction of appropriate disease markers have recently facilitated disease classification for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). Evaluation of inflammatory cell profiles, the differentiation of T-effector cells, characterization of remodeling processes such as fibrosis or edema formation, and innate or adaptive immunity products such as toll-like receptors and immunoglobulin provide tools to identify distinct disease entities within the group of chronic sinus diseases. This disease differentiation will not only increase our knowledge of the pathophysiology of sinusitis but may lead to new diagnostic and therapeutic strategies specifically targeted and adapted to the diagnosed disease entity.

 

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

 

The DelveInsight Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market report gives a thorough understanding of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Epidemiology

The epidemiology division’s Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) epidemiology segmented as the Total Chronic Rhinosinusitis (CRS) Prevalent cases, Total Chronic Rhinosinusitis without Nasal Polyps (CRSsNP), Prevalent cases, Gender-Specific Prevalent cases of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP), Prevalence of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) based on comorbidities. The report includes the prevalent Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Epidemiology

The epidemiology segment also provides the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 7MM prevalent cases of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) were 60,792,290 cases in 2020.

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Drug Chapters           

The drug chapter segment of the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) report encloses the detailed analysis of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps understand the Chronic Rhinosinusitis without Nasal Polyps clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Products detail in the report…

 

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Emerging Drugs

 

LYR-210: Lyra Therapeutics

On June 2, 2021, Lyra Therapeutics, Inc., a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to ear, nose, and throat (ENT) passages and other diseased tissues, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in major Asian markets, reported a strategic partnership and exclusive license agreement for the development and commercialization of LYR-210 in Europe and other Asian countries. LYR-210 is an anti-inflammatory, intra-nasal drug matrix in late-stage development designed to treat Chronic Rhinosinusitis (CRS), a debilitating inflammatory disease of the nasal passages.

 

LianBio will be responsible for the clinical development and commercialization of LYR-210 in the licensed territories, and Lyra will retain all rights to LYR-210 in all other geographies (LianBio, 2021)

Products detail in the report…

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Market Outlook

The Chronic Rhinosinusitis without Nasal Polyps market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Chronic Rhinosinusitis without Nasal Polyps market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)  market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market in 7MM is expected to change in the study period 2018–2030.

 

Key Findings

This section includes a glimpse of the Chronic Rhinosinusitis without Nasal Polyps market in 7MM. The market size of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in the seven major markets was found to be USD 5716.7 million in 2020.

 

The United States Market Outlook

This section provides a total of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market size and market size by therapies in the United States.

 

The United States accounts for the highest Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)  market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook

The total Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market size and market size by therapies in Japan are also mentioned.

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2018–2030. The analysis covers Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market uptake by drugs, patient uptake by therapies, and drug sales.

 

This helps understand the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake in making financial and regulatory decisions.

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stages. It also analyses Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) key players involved in developing targeted therapeutics.

 

Major players LYR-210 (Lyra Therapeutics), Dupixent (Sanofi), and many others are being assessed as potential therapies to be available in the market in the coming future.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chronic Rhinosinusitis without Nasal Polyps emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinions working Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapies treatment patterns or Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Rhinosinusitis without Nasal Polyps is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market

Report Highlights

  • In the coming years, Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). The launch of emerging therapies will significantly impact the Chronic Rhinosinusitis without Nasal Polyps market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP).
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Pipeline Analysis
  • Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Market share (%) distribution in 2020, and how would it look in 2030?
  • What would be the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) total market Size as well as market Size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the market’s key findings across 7MM, and which country will have the largest Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market Size during the forecast period (2021–2030)?
  • At what CAGR, the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market is expected to grow by 7MM during the forecast period (2021–2030)?
  • What would be the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the Chronic Rhinosinusitis without Nasal Polyps (CRsSNP) market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?
  • What is the historical Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population about Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?
  • Out of all 7MM countries, which country would have the highest prevalent Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) population during the forecast period (2021–2030)?
  • At what CAGR is the population expected to grow by 7MM during the forecast period (2021–2030)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?
  • What are the current treatment guidelines for treating Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in the USA, Europe, and Japan?
  • What are the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?
  • How many therapies are developed by each company for the treatment of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?
  • How many emerging therapies are in the mid-stage and late development stages to treat Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) and their status?
  • What are the key designations that have been granted for the emerging therapies for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?
  • What are the global historical and forecasted markets of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market
  • To understand the future market competition in the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market
  • To understand the future market competition in the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) market

1. Key Insights

2. Chronic Rhinosinusitis without Nasal Polyps Market Overview at a Glance

3. Market Share (%) Distribution of Chronic Rhinosinusitis without Nasal Polyps in 2018

4. Market Share (%) Distribution of Chronic Rhinosinusitis without Nasal Polyps  in 2030

5. Executive summary

6. Organizations

7. Disease Background and Overview

7.1. Introduction

7.2. Classification

7.3. Causes

7.4. Symptoms and Complications

7.5. Pathophysiology

7.6. Diagnosis

8. Epidemiology and Patient Population

9. Key Findings

10. Total Diagnosed Prevalent Population of Chronic Rhinosinusitis without Nasal Polyps

11. Country Wise-Epidemiology of Chronic Rhinosinusitis without Nasal Polyps

12. The United States

12.1. Assumptions and Rationale

12.1.1. Total Prevalence of Chronic Rhinosinusitis in the United States

12.1.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United States

12.1.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United States

12.1.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13. EU5 Countries

13.1. Germany

13.1.1. Total Prevalence of Chronic Rhinosinusitis in Germany

13.1.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany

13.1.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany

13.1.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.2. France

13.2.1. Total Prevalence of Chronic Rhinosinusitis in France

13.2.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France

13.2.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France

13.2.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.3. Italy

13.3.1. Total Prevalence of Chronic Rhinosinusitis in Italy

13.3.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy

13.3.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy

13.3.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.4. Spain

13.4.1. Total Prevalence of Chronic Rhinosinusitis in Spain

13.4.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Spain

13.4.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Spain

13.4.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.5. The United Kingdom

13.5.1. Total Prevalence of Chronic Rhinosinusitis in the UK

13.5.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in  the UK

13.5.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the UK

13.5.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.6. Japan

13.6.1. Total Prevalence of Chronic Rhinosinusitis in Japan

13.6.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan

13.6.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan

13.6.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

14. Treatment Goals

15. Patient Journey for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

16. Unmet Needs

17. Marketed Drugs

17.1. Corticosteroids

17.2. Antihistamines

17.3. Antibiotics

18. Emerging Therapies

18.1. LYR-210: Lyra Therapeutics

18.1.1. Product Description

18.1.2. Other development activities

18.1.3. Clinical Development

18.1.4. Clinical Trials Information

18.1. Dupilumab: Sanofi

18.1.1. Product Description

18.1.2. Other development activities

18.1.3. Clinical Development

18.1.4. Clinical Trials Information

To be continued in the Report

20. Key Findings

21. Total Market Size of Chronic Rhinosinusitis without Nasal Polyps in 7MM

22. Market Outlook by Country

23. Market Outlook

24. United States Market Size

24.1. Total Market Size of Chronic Rhinosinusitis without Nasal Polyps

24.2. Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies

25. EU-5

25.1. Germany

25.1.1. Total Market size of Chronic Rhinosinusitis without Nasal Polyps

25.1.2. Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies

25.2. France

25.2.1. Total Market size of Chronic Rhinosinusitis without Nasal Polyps

25.2.2. Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies

25.3. Italy

25.3.1. Total Market size of Chronic Rhinosinusitis without Nasal Polyps

25.3.2. Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies

25.4. Spain

25.4.1. Total Market size of Chronic Rhinosinusitis without Nasal Polyps

25.4.2. Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies

25.5. United Kingdom

25.5.1. Total Market Size of Chronic Rhinosinusitis without Nasal Polyps

25.5.2. Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies

26. Japan: Market Outlook

26.1. Total Market Size of Chronic Rhinosinusitis without Nasal Polyps

26.2. Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies

27. Market Drivers

28. Market Barriers

29. KOL

30. SWOT Analysis

31. Appendix

32. Report Methodology

33. DelveInsight Capabilities

34. Disclaimer

35. About DelveInsight

List of Table

Table 1: Summary of Chronic Rhinosinusitis without Nasal polyps, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Organizations contributing towards the fight against Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

Table 3: Total Prevalent Patient Population of Chronic Rhinosinusitis without Nasal Polyps in 7MM in 1000’s (2018–2030)

Table 4: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in the United States (2018–2030)

Table 5: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in the United States   (2018–2030)

Table 6: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United States (2018–2030)

Table 7: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in the United States (2018–2030)

Table 8: Total Prevalent Cases of Chronic Rhinosinusitis in Germany (2018–2030)

Table 9: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Germany (2018–2030)

Table 10: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany (2018–2030)

Table 11: Sub-type Specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany (2018–2030)

Table 12: Total Prevalent Cases of Chronic Rhinosinusitis in France (2018–2030)

Table 13: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in France (2018–2030)

Table 14: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France (2018–2030)

Table 15: Sub-type Specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France (2018–2030)

Table 16: Total Prevalent Cases of Chronic Rhinosinusitis in Italy (2018–2030)

Table 17: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Italy (2018–2030)

Table 18: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy (2018–2030)

Table 19: Sub-type Specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy  (2018–2030)

Table 20: Total Prevalent Cases of Chronic rhinosinusitis in Spain (2018–2030)

Table 22: Age-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United Kingdom (2018–2030)

Table 23: Prevalent cases of Chronic Rhinosinusitis without Nasal Polyps in Japan (2018–2030)

Table 24: Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Etiology-specific factors in Japan (2018–2030)

Table 25: Age-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan (2018–2030)

Table 26: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United Kingdom (2018–2030)

Table 27: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in the United Kingdom (2018–2030)

Table 28: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in Japan (2018–2030)

Table 29: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Japan (2018–2030)

Table 30: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan (2018–2030)

Table 31: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Japan (2018–2030)

Table 32: LYR-210, Clinical Trial Description, 2021

Table 33: Dupixent (Duplimab), Clinical Trial Description, 2021

Table 34: Benralizumab (KHK4563), Clinical Trial Description, 2021

Table 35: GB001, Clinical Trial Description, 2021

Table 36: 7 Major Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 37: United States Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 38: United States Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Table 39: Germany Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 40: Germany Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Table 41: France Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 42: France Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Table 43: Italy Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 44: Italy Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Table 45: Spain Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 46: Spain Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Table 47: United Kingdom Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 48: United Kingdom Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Table 49: Japan Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Table 50: Japan Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

List of Figures

Figure 1: Schematic depiction of pathological mechanisms of Chronic Rhinosinusitis without Nasal Polyps.

Figure 2: Chronic Rhinosinusitis without Nasal Polyps. T Cell Biology

Figure 3: Risk factors for the development of CRS

Figure 4: Total Prevalent Population of Chronic Rhinosinusitis without Nasal Polyps in 7MM in 1000’s (2018–2030)

Figure 5: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in the United States (2018–2030)

Figure 6: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in the United States (2018–2030)

Figure 7: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United States (2018–2030)

Figure 8: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in the United States (2018–2030)

Figure 9: Total Prevalent Cases of Chronic Rhinosinusitis in Germany (2018–2030)

Figure 10: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Germany (2018–2030)

Figure 11: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany (2018–2030)

Figure 12: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Germany (2018–2030)

Figure 13: Total Prevalent Cases of Chronic Rhinosinusitis in France (2018–2030)

Figure 14: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in France (2018–2030)

Figure 15: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France (2018–2030)

Figure 16: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in France (2018–2030)

Figure 17: Total Prevalent Cases of Chronic Rhinosinusitis in Italy (2018–2030)

Figure 18: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Italy (2018–2030)

Figure 19: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy (2018–2030)

Figure 20: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Italy (2018–2030)

Figure 21: Total Prevalent Cases of Chronic Rhinosinusitis in Spain (2018–2030)

Figure 22: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Spain (2018–2030)

Figure 23: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Spain (2018–2030)

Figure 24: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Spain (2018–2030)

Figure 25: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in the United Kingdom (2018–2030)

Figure 26: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in the United Kingdom (2018–2030)

Figure 27: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United Kingdom (2018–2030)

Figure 28: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in the United   Kingdom (2018–2030)

Figure 29: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in Japan (2018–2030)

Figure 30: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Japan (2018–2030)

Figure 31: Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan (2018–2030)

Figure 32: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Japan (2018–2030)

Figure 33: 7 Major Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Figure 34: 7 Major Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 35: Total Market Size of Chronic Rhinosinusitis without Nasal Polyps in the United States, USD Million (2018–2030)

Figure 36: The United States Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 37: Total Market Size of Chronic Rhinosinusitis without Nasal Polyps in Germany, USD Million (2018–2030)

Figure 38: The Germany Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 39: Market Size of Chronic Rhinosinusitis without Nasal Polyps in France, USD Million (2018–2030)

Figure 40: The France Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 41: Market Size of Chronic Rhinosinusitis without Nasal Polyps in Italy, USD Million (2018–2030)

Figure 42: The Italy Market Size of Chronic rhino sinusitis without nasal polyps by Therapies in USD Million (2018–2030)

Figure 43: Market Size of Chronic Rhinosinusitis without Nasal Polyps in Spain, USD Million (2018–2030)

Figure 44: The Spain Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 45: Market Size of Chronic Rhinosinusitis without Nasal Polyps in the United Kingdom, USD Million (2018–2030)

Figure 46: The United Kingdom Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 47: Market Size of Chronic Rhinosinusitis without Nasal Polyps in Japan, USD Million (2018–2030)

Figure 48: The Japan Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Lyra Therapeutics
Sanofi

 

Forward to Friend

Need A Quote